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A B S T R A C T
Background
Periampullary cancer includes cancer of the head and neck of the pancreas, cancer of the distal end of the bile duct, cancer of the ampulla
of Vater, and cancer of the second part of the duodenum. Surgical resection is the only established potentially curative treatment for
pancreatic and periampullary cancer. A considerable proportion of patients undergo unnecessary laparotomy because of underestimation
of the extent of the cancer on computed tomography (CT) scanning. Other imaging methods such as magnetic resonance imaging
(MRI), positron emission tomography (PET), PET-CT, and endoscopic ultrasound (EUS) have been used to detect local invasion or
distant metastases not visualised on CT scanning which could prevent unnecessary laparotomy. No systematic review or meta-analysis
has examined the role of different imaging modalities in assessing the resectability with curative intent in patients with pancreatic and
periampullary cancer.
Objectives
To determine the diagnostic accuracy of MRI, PET scan, and EUS performed as an add-on test or PET-CT as a replacement test to
CT scanning in detecting curative resectability in pancreatic and periampullary cancer.
Search methods
We searched MEDLINE, Embase, Science Citation Index Expanded, and Health Technology Assessment (HTA) databases up to 5
November 2015. Two review authors independently screened the references and selected the studies for inclusion. We also searched for
articles related to the included studies by performing the “related search” function in MEDLINE (OvidSP) and Embase (OvidSP) and
a “citing reference” search (by searching the articles that cite the included articles).
1Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with
curative intent in pancreatic and periampullary cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selection criteria
We included diagnostic accuracy studies of MRI, PET scan, PET-CT, and EUS in patients with potentially resectable pancreatic and
periampullary cancer on CT scan. We accepted any criteria of resectability used in the studies. We included studies irrespective of
language, publication status, or study design (prospective or retrospective). We excluded case-control studies.
Data collection and analysis
Two review authors independently performed data extraction and quality assessment using the QUADAS-2 (quality assessment of
diagnostic accuracy studies - 2) tool. Although we planned to use bivariate methods for analysis of sensitivities and specificities, we
were able to fit only the univariate fixed-effect models for both sensitivity and specificity because of the paucity of data. We calculated
the probability of unresectability in patients who had a positive index test (post-test probability of unresectability in people with a
positive test result) and in those with negative index test (post-test probability of unresectability in people with a positive test result)
using the mean probability of unresectability (pre-test probability) from the included studies and the positive and negative likelihood
ratios derived from the model. The difference between the pre-test and post-test probabilities gave the overall added value of the index
test compared to the standard practice of CT scan staging alone.
Main results
Only two studies (34 participants) met the inclusion criteria of this systematic review. Both studies evaluated the diagnostic test accuracy
of EUS in assessing the resectability with curative intent in pancreatic cancers. There was low concerns about applicability for most
domains in both studies. The overall risk of bias was low in one study and unclear or high in the second study. The mean probability of
unresectable disease after CT scan across studies was 60.5% (that is 61 out of 100 patients who had resectable cancer after CT scan had
unresectable disease on laparotomy). The summary estimate of sensitivity of EUS for unresectability was 0.87 (95% confidence interval
(CI) 0.54 to 0.97) and the summary estimate of specificity for unresectability was 0.80 (95% CI 0.40 to 0.96). The positive likelihood
ratio and negative likelihood ratio were 4.3 (95% CI 1.0 to 18.6) and 0.2 (95% CI 0.0 to 0.8) respectively. At the mean pre-test
probability of 60.5%, the post-test probability of unresectable disease for people with a positive EUS (EUS indicating unresectability)
was 86.9% (95% CI 60.9% to 96.6%) and the post-test probability of unresectable disease for people with a negative EUS (EUS
indicating resectability) was 20.0% (5.1% to 53.7%). This means that 13% of people (95% CI 3% to 39%) with positive EUS have
potentially resectable cancer and 20% (5% to 53%) of people with negative EUS have unresectable cancer.
Authors’ conclusions
Based on two small studies, there is significant uncertainty in the utility of EUS in people with pancreatic cancer found to have resectable
disease on CT scan. No studies have assessed the utility of EUS in people with periampullary cancer.
There is no evidence to suggest that it should be performed routinely in people with pancreatic cancer or periampullary cancer found
to have resectable disease on CT scan.
P L A I N L A N G U A G E S U M M A R Y
Diagnostic accuracy of different scans following a CT scan for assessing whether pancreatic and periampullary cancer is
resectable
Review question
How well do different scans identify whether pancreatic and periampullary cancer is resectable (can be surgically removed) in patients
with pancreatic cancer in whom computed tomography (CT) scan suggests that the cancer can be removed?
CT scan involves a series of X-rays which are combined by a computer to provide detailed images of the area of the body X-rayed.
Background
The pancreas is an organ situated in the abdomen close to the junction of the stomach and small bowel. It secretes digestive juices
that are necessary for the digestion of all food materials. The digestive juices secreted in the pancreas drain into the upper part of the
small bowel via the pancreatic duct. The bile duct is a tube which drains bile from the liver and gallbladder. The pancreatic and bile
ducts share a common path just before they drain into the small bowel. This area is called the periampullary region. Surgical removal
is the only potentially curative treatment for cancers arising from the pancreatic and periampullary regions. A considerable proportion
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of patients undergo unnecessary major open abdominal exploratory operation (laparotomy) because their CT scan has underestimated
the spread of cancer. If the cancer is spread within the abdomen as identified during the major open operation, the main treatment is
chemotherapy which does not cure the cancer but may improve survival. Thus the major open abdominal operation with its associated
risks can be avoided if the spread of cancer within the abdomen is known before the major operation. Determining the extent of cancer
is called “staging” the cancer. Usually the minimum test used for staging is the CT scan. However, CT scan can understage the cancer,
i.e. it can underestimate the spread of cancer. Various other scans can be used in addition to CT scan in order to find out if pancreatic
cancer is resectable (able to be surgically removed). These include the following tests.
1. Magnetic resonance imaging (MRI): use of a powerful magnet to produce images of different tissues of the body.
2. Positron emission tomography (PET scan): small amount of radioactive glucose (sugar) is used to differentiate between different
tissues. It utilises the property that cancer cells often use more glucose than normal cells).
3. Endoscopic ultrasound (EUS); the use of an endoscope, a camera introduced into the body cavities to view the inside of the body.
An ultrasound (high-energy sound waves) probe at the end of the endoscope is used to differentiate different tissues.
In addition, a combination of PET-CT may be performed instead of CT.
Different studies report different accuracy of these tests in assessing whether the cancer can be removed. In this review, we identified all
such studies and used appropriate mathematical methods to identify the average diagnostic accuracy of these tests for staging pancreatic
and periampullary cancers considered to be removable after a CT scan.
Study characteristics
We included two studies with a total of 34 patients in this review. Both studies evaluated the diagnostic performance of EUS. This
evidence is current to 5 November 2015.
Quality of the evidence
Of the two studies, one study was conducted as well as such a study could be conducted. The methodological quality of the other study
was poor.
Key results
The two included studies showed that in those people with pancreatic cancer in whom CT alone showed their cancer was capable of
being fully surgically removed, 61% (61 out of 100) would prove to have cancer that was too fully spread to make this possible when a
laparotomy was attempted. Due to the small sample size, there is significant uncertainty in the utility of EUS in people with pancreatic
cancer found to have resectable disease on CT scan. There is no evidence to suggest that it should be performed routinely in people
with pancreatic cancer found to have resectable disease on CT scan.
B A C K G R O U N D
Please see Appendix 1 for a glossary of terms.
Periampullary cancer develops near the ampulla of Vater (National
Cancer Institute 2014a). Periampullary cancer includes cancer of
the head and neck of the pancreas, cancer of the distal end of
the bile duct, cancer of the ampulla of Vater, and cancer of the
second part of the duodenum. Pancreatic cancer (pancreatic can-
cer) is the tenth most common cancer in the USA, the fifth most
common cause of cancer-related mortality in the east and the
fourth most common cause of cancer-related mortality in the west
(Parkin 2001; Parkin 2005; Yamamoto 1998). In 2012, 338,000
new patients were diagnosed with pancreatic cancer and therewere
330,000 deaths due to pancreatic cancer globally (IARC 2014).
There is global variation in the incidence of pancreatic cancers,
with an age-standardised annual incidence rate of 7.2 per 100,000
population in the more developed regions and an age-standard-
ised annual incidence rate of 2.8 per 100,000 population in the
less developed regions (IARC 2014). A similar trend is noted in
the age-standardised annual mortality rates, of 6.8 per 100,000
population in themore developed regions and an age-standardised
annual mortality rate of 2.7 per 100,000 population in the less
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developed regions due to pancreatic cancer (IARC 2014).
Pancreaticoduodenectomy is the main treatment for cancers that
arise in the head of the pancreas, ampulla, and second part of
the duodenum. Surgical resection is generally considered the only
treatment that can cure pancreatic cancer. However, only 15% to
20% of patients with pancreatic cancers undergo potentially cu-
rative resection (Conlon 1996; Engelken 2003; Michelassi 1989;
Shahrudin 1997; Smith 2008). The overall five-year survival af-
ter radical resection ranges from 7% to 25% (Cameron 1993;
Livingston 1991; Niederhuber 1995; Nitecki 1995; Orr 2010;
Trede 1990), with a median survival of 11 to 15 months (British
Management Guideline 2005). With adjuvant chemotherapy, the
median survival after radical resection varies between 14 and 24
months (Liao 2013). In all other patients, the cancers are not
resected because of infiltration of local structures, disseminated
disease, or because the patient is deemed unfit to undergo major
surgery. Computed tomography (CT) scan is generally used for
staging pancreatic and periampullary cancers (National Cancer
Institute 2014b). Despite undergoing routine CT scanning to
stage the disease, a substantial proportion of patients (approxi-
mately 40%) undergo unnecessary laparotomy (opening the ab-
domen using a large incision) with lack of curative resectability
identified only during the laparotomy (Allen 2016). Staging la-
paroscopy or diagnostic laparoscopy may decrease the proportion
of patients that undergo unnecessary laparotomy to approximately
17% (Allen 2016). Tests, such as magnetic resonance imaging
(MRI), positron emission tomography (PET) scan, or endoscopic
ultrasound (EUS), may be used in addition to CT scan to assess
resectability with curative intent and decrease the proportion of
patients who undergo unnecessary laparotomy.
Target condition being diagnosed
Inability to perform curative resectability of pancreatic and peri-
ampullary cancer (“unresectable” cancers)
Index test(s)
MRI
MRI involves the use of a powerful magnet to produce images
of different tissues of the body. This is also called nuclear MRI
(NMRI) (National Cancer Institute 2014c). Features, such as ex-
tent of the cancer in terms of involvement of adjacent structures
and spread of cancer to distant areas (metastases), are taken into
account to assess resectability with curative intent. The radiologist
usually interprets the images.
PET
PET involves the use of a small amount of radioactive glucose
(sugar) to differentiate between different tissues. It utilises the
property that cancer cells often usemore glucose than normal cells.
It is also called PET scan (National Cancer Institute 2014d). This
is a form of functional imaging. Cancerous lesions appear as areas
of increased uptake. The presence of cancer in different locations
and metastases are taken into account to assess resectability with
curative intent. The radiologist usually interprets the images.
PET-CT scan
PET scan can be combined with CT scan (PET-CT scan), with
both tests performed at the same time (National Cancer Institute
2014e). This allows superimposition of the two images by identify-
ing corresponding points of the body in the two scans (coregistra-
tion) and allows the combination of the functional imaging (PET
scan) with an anatomical imaging (CT scan), which may result
in better diagnostic accuracy than either modality alone (National
Cancer Institute 2014e). Usually, the radiologist interprets the im-
ages.
EUS
EUS involves the use of an endoscope, a camera introduced into
the body cavities to view the inside of the body. An ultrasound
(high-energy sound waves) probe at the end of the endoscope is
used todifferentiate different tissues. This is also called endosonog-
raphy and EUS (National Cancer Institute 2014f). Local extent
and metastases are taken into account to assess resectability with
curative intent. The endoscopist usually interprets the images.
Clinical pathway
There is no standard algorithm currently available to assess the
resectability of pancreatic and periampullary cancers, with differ-
ent clinicians following their own algorithms based on either their
clinical experience or what they have been taught. Currently, al-
most all algorithms include a CT scan as one of the tests (National
Cancer Institute 2014b). CT may be the only test performed be-
fore laparotomy. Other tests, such as diagnostic laparoscopy, PET
(PET scan or PET-CT scan), MRI, or EUS, may be used in ad-
dition to CT scan to assess resectability. We have presented the
possible clinical pathway in the staging of pancreatic cancers in
Figure 1.
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Figure 1. Clinical pathway for the staging of pancreatic cancers.Abbreviations: PET: positron emission
tomography; MRI: magnetic resonance imaging; EUS: endoscopic ultrasound; CT: computed tomography.
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Prior test(s)
The minimum prior test should be CT and the cancer should be
resectable with curative intent on the basis of the CT scan. Other
imaging modalities, such as MRI, PET scan, PET-CT, or EUS,
might be used in addition to CT scanning to assess resectability
before performing the imaging modality being assessed.
Role of index test(s)
MRI, PET scan, and EUS can be considered as add-on tests to the
CT scan prior to laparotomy done with the intention of perform-
ing a potentially curative resection. PET-CT scan can be consid-
ered as a replacement for CT scan prior to laparotomy done with
the intention of performing a potentially curative resection. It can
also be considered as an add-on test to the CT scan prior to la-
parotomy. Although it appears strange to use PET-CT scan as an
add-on test to CT scan, such an approach is possible if patients are
referred to the referral centre with a CT scan. It should be noted
that PET and CT scan should be performed simultaneously to
allow coregistration. However, the problem with PET-CT scan as
a replacement for CT scan is that PET-CT has to be performed
without contrasts and hence PET-CT alone may not provide as
good an information as PET-CT along with conventional CT
scan.
Alternative test(s)
Diagnostic laparoscopy or laparoscopic ultrasound may be used
as an alternative test to these imaging modalities in patients con-
sidered to have CT resectable pancreatic and periampullary can-
cer (Allen 2016; Hariharan 2010). Another Cochrane review has
assessed the accuracy of diagnostic laparoscopy (Allen 2016).
Rationale
The different imaging modalities identify the extent of local
spread, including invasion of adjacent blood vessels, andmay iden-
tify distal metastases (MRI, PET scan, PET-CT scan). If this add-
on test (or replacement test in the case of PET-CT scan in patients
who are referredwithout a CT scan) can identify unresectable can-
cers without laparotomy, it might decrease the costs and morbid-
ity associated with unnecessary laparotomy. Currently there is no
Cochrane review that has assessed the diagnostic accuracy of these
imaging modalities in the assessment of the curative resectability
of pancreatic and periampullary cancers.
O B J E C T I V E S
To determine the diagnostic accuracy of MRI, PET scan, and
EUS performed as an add-on test or PET-CT as an add-on or
replacement test to CT scanning in detecting curative resectability
in pancreatic and periampullary cancer.
Secondary objectives
We planned to explore the following sources of heterogeneity.
1. Studies at low risk of bias versus those at unclear or high
risk of bias (as assessed by the QUADAS-2 tool, recommended
by the Cochrane Diagnostic Test Accuracy Group) (Whiting
2006; Whiting 2011).
2. Full text publications versus abstracts (this can give a clue
about publication bias since there may be an association between
the results of the study and the study reaching full publication
status) (Eloubeidi 2001).
3. Prospective studies versus retrospective studies.
4. Proportion of patients with pancreatic cancer, ampullary
cancer, and duodenal cancers (although classified as
periampullary cancers they each have a different prognosis)
(Klempnauer 1995). The additional value of the imaging
modalities may be different because of the extent of spread in
these different types of periampullary cancers.
5. Different definitions for resectable cancer on laparotomy.
Different surgeons may consider cancer unresectable differently
i.e. different surgeons would have different criteria for
unresectability on laparotomy (other than the consensus criteria
for resectability). For example, one surgeon may judge that the
cancer is unresectable on laparotomy because of the involvement
of the local vessels (mainly portal vein and superior mesenteric
vein) and consider the reference standard to be positive. This
would result in a false negative result for the imaging modality.
Another surgeon may judge the same cancer to be resectable
despite the involvement of the vessel and proceed with resection.
The reference standard would be negative in this situation,
which would result in a true negative result for the imaging
modality. This might have an intrinsic threshold effect.
6. Additional pre-tests performed (besides CT scan). This can
alter the pre-test probability of unresectability and can help in
the assessment of the additional value of the imaging modality
under various situations.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We only included studies that provided diagnostic test accuracy
data (true positive, false positive, false negative, and true negative)
on the different imaging modalities mentioned above in the ap-
propriate patient population (see below) irrespective of language,
publication status, or whether data were collected prospectively or
retrospectively. However, we excluded case reports which do not
provide sufficient diagnostic test accuracy data. We also planned
to exclude any identified case-control studies because case-control
studies are prone to bias (Whiting 2011).
Participants
Adults considered for curative resection of pancreatic or peri-
ampullary cancer on the basis of CT findings, who were fit to un-
dergo major surgery. We included patients in this review irrespec-
tive of whether they underwent other imaging modalities prior to
imaging modality being assessed.
Index tests
MRI, PET scan, PET-CT scan, or EUS.
Target conditions
The target conditions were unresectable pancreatic and peri-
ampullary cancers, that is, we considered the imaging modality
a positive test if the pancreatic or periampullary cancer is unre-
sectable with curative intent. In these cancers it is not possible
to perform curative resectability. Clinically, it may not be easy to
distinguish head of pancreas cancers, ampullary cancers, and can-
cer of the second part of the duodenum. The treatment for these
different cancers is the same, i.e. pancreatoduodenectomy and the
final confirmation as to the origin of these cancers may be done
after resection without definitive diagnosis of the origin of the can-
cer, as long as the cancers are resectable. So we considered these
cancers together. There are no uniform criteria for resectability
of pancreatic and periampullary cancer. Consensus exists for the
definition of borderline resectable cancers (Abrams 2009). There-
fore, where there is less tissue involvement than in a borderline
resectable cancer the tumour can be considered as resectable. We
accepted any criteria of resectability used by the study authors and
acknowledge that this could potentially create a threshold effect.
In general, the cancer will not be resected if liver, peritoneal, or
distal nodal metastases were noted, or if the cancer had invaded
important adjacent blood vessels that are beyond the criteria for
borderline resectable cancers (for example, greater than 180° in-
volvement of the superior mesenteric artery) (Abrams 2009).
Reference standards
Confirmation of liver, peritoneal, or nodal metastatic involvement
by histopathological examination of suspicious (liver, peritoneal,
or nodal metastatic) lesions obtained at diagnostic laparoscopy or
laparotomy. We accepted only paraffin section histology as the
reference standard. In clinical practice, depending on the urgency
of the results, a frozen section biopsy may be done to obtain im-
mediate results. However, this is always confirmed by subsequent
paraffin section histology (which can take several days) because
frozen section biopsy is not as reliable as paraffin section histology.
We also accepted the surgeon’s judgement of unresectability at la-
parotomy when biopsy confirmation was not possible as an alter-
nate reference standard. For example, if the tumour has invaded
the adjacent blood vessels the surgeon may not resect the tumour
because of the danger posed by resecting part of a large blood ves-
sel, and so biopsy confirmation cannot be obtained. However, it
should be noted that a surgeon’s judgement of unresectability at
laparotomy is a subjective decision and is a possible source of error
in the reference standard. In the absence of an ethical and true
gold standard, we accepted this as a reference standard.
Search methods for identification of studies
We included all studies irrespective of the language of publication
and publication status. We translated any non-English articles we
found to assess eligibility.
Electronic searches
We searched the following databases on 5 November 2015.
1. MEDLINE (In-Process & Non-Indexed Citations) via
OvidSP (January 1946 to 5 November 2015; Appendix 2).
2. Embase via OvidSP (January 1947 to 5 November 2015;
Appendix 3).
3. Science Citation Index Expanded (including Conference
Proceedings Citation Index - Science) via Web of Knowledge
(January 1980 to 5 November 2015; Appendix 4).
4. National Insitute for Health Research - Health Technology
Assessment (NIHR HTA) (November 2015) through the
University of York Centre for Reviews and Dissemination (
www.crd.york.ac.uk/CRDWeb/) (Appendix 5).
We included sensitivity maximising diagnostic filters for searching
MEDLINE and Embase databases (Haynes 2004; Wilczynski
2005). This is because we retrieved more than 40,000 references
when we used the original searches without the filters.
Searching other resources
We searched the references of the included studies to identify addi-
tional studies. We also searched for articles related to the included
studies by performing the “related search” function in MEDLINE
(OvidSP) andEmbase (OvidSP) and a “citing reference” search (by
searching the articles which cite the included articles) (Sampson
2008) in ScienceCitation IndexExpanded,MEDLINE (OvidSP),
and Embase (OvidSP).
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Data collection and analysis
Selection of studies
Two review authors (DT and KSG) independently screened the
results ofthe search strategy to identify relevant studies. We ob-
tained the full-text articles of references that at least one of the
review authors considered relevant. Two review authors (DT and
KSG or DR) independently screened the full-text papers against
the inclusion criteria. We did not have any differences in study se-
lection based on our full-text article assessments. If the eligibility of
the report was unclear, we attempted to contact the study authors
to seek clarification. Since we were unable to contact the study
authors, we excluded the reports. We listed all excluded studies
and their reasons for exclusion in the Characteristics of excluded
studies table). Also, we constructed a PRISMA diagram to illus-
trate the study selection process.
Data extraction and management
Two review authors (DT and KSG) independently extracted the
following data from each included study using a data extraction
form that KSG designed and piloted. We resolved any differences
by discussion.
1. First author.
2. Year of publication.
3. Study design (prospective or retrospective; cross-sectional
studies or randomised controlled trials).
4. Inclusion and exclusion criteria for individual studies.
5. Total number of patients.
6. Number of females.
7. Average age of the participants.
8. Type of cancer (i.e. head and neck of pancreas, body and
tail of pancreas, ampullary cancers, duodenal cancer).
9. Criteria for unresectability at the index test and at
laparotomy (reference standard).
10. Preoperative tests carried out prior to index test.
11. Description of the index test.
12. Reference standard.
13. Number of true positives, false positives, false negatives,
and true negatives.
The unit of analysis was the patient, meaning that if multiple
metastases or multiple infiltrations of adjacent structures were
found in a patient with a negative index test, we planned to con-
sider the number of false negatives to be one. This is because it is
the presence, rather than the number of metastases or the number
of infiltrations of adjacent structures, that is important in deter-
mining the curative resectability of patients. We planned to con-
sider patients with uninterpretable index test results (no matter
the reason given for lack of interpretation) as negative for the test
since in clinical practice laparotomy would be carried out on these
patients. However, we planned to include such patients in the
analysis only if the results of laparotomy were available.We sought
further information from the study authors if necessary.
If the same study reported multiple index tests, we planned to
extract the number of true positives, false positives, false negatives,
and true negatives for each index test. If there was an overlap of
participants between multiple reports as suspected by common
authors and centres, we planned to contact the study authors to
seek clarification about the overlap. If wewere unable to contact the
authors, we planned to extract themaximum possible information
from all the reports. However, we did not any find such reports.
Assessment of methodological quality
Two review authors (DT and KSG) independently assessed study
quality using the QUADAS-2 assessment tool (Whiting 2006;
Whiting 2011).We resolved differences through discussion, based
on the criteria published in the protocol (Gurusamy 2015). We
have presented the criteria that we used to classify the different
studies in Table 1. We considered studies which are classified as
“low risk of bias” and “low concern” in all the domains as studies
with high methodological quality. We planned to present the re-
sults in a “Risk of bias” summary and graphs, but because there
were only two studies, we have presented the “Risk of bias” sum-
mary only.
Statistical analysis and data synthesis
We plotted study estimates of sensitivity and specificity on for-
est plots and in receiver operating characteristic (ROC) space to
explore between study variation in the performance of each test.
To estimate the summary sensitivity and specificity of each test,
we planned to perform the meta-analysis by fitting the bivariate
model (Chu 2006; Reitsma 2005). This model accounts for be-
tween-study variability in estimates of sensitivity and specificity
through the inclusion of random effects for the logit sensitivity
and logit specificity parameters of the bivariate model. If sparse
data results in unreliable estimation of the covariance matrix of
the random effects (as indicated by very large variance of logit
sensitivity and specificity or if there was lack of convergence), we
tried other alternate models including the random-effects model,
ignoring the inverse correlation between sensitivities and speci-
ficities in the different studies due to intrinsic threshold effect,
and the fixed-effect model for either sensitivity or specificity or
both after visualising the forest plots and summary receiver oper-
ating characteristics (SROC) plots (Takwoingi 2015). We based
our choice between the different models on the distribution of
sensitivities and specificities as noted in the forest plots or ROC
space. We also planned to use the model fit as indicated by the−2
log likelihood and planned to consider the model with the lower
−2 log likelihood to be the better model.
We planned to compare the diagnostic accuracy of the tests by
including covariate terms for test type (MRI, PET, PET-CT, or
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EUS) in the bivariate model to estimate differences in the sensi-
tivity and specificity of the tests. We planned to allow both the
sensitivity and specificity to vary by covariate. In addition, we also
planned to permit the variances of the random effects and their
covariance to also depend on test type thus allowing the variances
to differ between tests. We planned to use likelihood ratio tests
to compare the model with and without covariate (test type). We
planned to use a P value of less than 0.05 for the likelihood ra-
tio test to indicate differences in the diagnostic accuracy between
the tests. If studies that reported different tests in the same study
population were available from at least four studies, we planned
to perform a direct head-to-head comparison by limiting the test
comparison to such studies. We planned to calculate the relative
sensitivities and specificities for each pairwise comparison of tests.
We performed the meta-analysis using the NLMixed command in
SAS version 9.3 (SAS Institute Inc, Cary, North Carolina, USA).
We created a graph of pre-test probabilities (using the observed
median and range of prevalence from the included studies) against
post-test probabilities. We calculated the post-test probabilities
using these pre-test probabilities and the summary positive and
negative likelihood ratios. We calculated the summary likelihood
ratios and their confidence intervals (CIs) from the functions of
the parameter estimates from the model that we fitted to estimate
the summary sensitivities and specificities. Post-test probability
associated with positive test is the probability of having the tar-
get condition (unresectability) on the basis of a positive test re-
sult (unresectable disease) and is the same as the term “positive
predictive value” used in a single diagnostic accuracy study. Post-
test probability associated with a negative test is the probability
of having the target condition (unresectability) on the basis of a
negative test result (resectable disease) and is 1 - “negative predic-
tive value”. Negative predictive value is the term used in a single
diagnostic accuracy study to indicate the chance that the patient
has no target condition when the test is negative. We planned to
report the summary sensitivity, specificity, positive and negative
likelihood ratios, and post-test probabilities for the median, lower
quartile, and upper quartile of the pre-test probabilities.
Investigations of heterogeneity
Weplanned to explore heterogeneity by using the different sources
of heterogeneity as covariate(s) in the hierarchical summary re-
ceiver operating characteristics (HSROC) model. Of the six
sources of heterogeneity we listed in the Secondary objectives sec-
tion, we planned to deal with all items other than proportion of
patients with pancreatic cancer, ampullary cancer, and duodenal
cancer as categorical covariates. We planned to use the proportion
of patients with pancreatic cancer, ampullary cancer, and duode-
nal cancer as continuous covariates in the regression model. We
planned to employ likelihood ratio tests to compare the model
with and without covariate. We planned to use a P value of less
than 0.05 for the likelihood ratio test to indicate that the covariate
was a potential source of heterogeneity.
Sensitivity analyses
We did not plan to perform any sensitivity analyses except when
the data available from the studies was ambiguous (for example,
the numbers in the text differed from the numbers in the figures),
in which case we planned to assess the impact of different data
used by a sensitivity analysis.
Assessment of reporting bias
We planned to investigate whether the summary sensitivity and
specificity differed between studies published as full texts and those
available only as abstracts using the methods we described in the
Investigations of heterogeneity section.
R E S U L T S
Results of the search
We identified a total of 23,346 references through electronic
searches of MEDLINE (OvidSP; N = 9763), Embase (OvidSP; N
= 8097), Science Citation Index expanded (Web of Knowledge;
includes Conference Proceedings Citation Index- Science; N =
5412), and HTA (Centre for Reviews and Dissemination; (N =
74). After we removed duplicate references, there were 14,590 ar-
ticles remaining. We excluded 14,384 clearly irrelevant references
through reading abstracts. We retrieved the full-text publication
of 206 references for further detailed assessment. We excluded 204
references for the reasons in the Characteristics of excluded studies
section. Two diagnostic accuracy studies (two references) fulfilled
the inclusion criteria (see the Characteristics of included studies
section). We have presented a study flow diagram in Figure 2.
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Figure 2. Study flow diagram.
Included studies
Two studies with small sample sizes met the inclusion criteria. One
study was a prospective study (Ahmad 2001), while the other was a
retrospective study (Ardengh 2003). These two studies included a
total of 38 participants with pancreatic cancer . Ardengh 2003 in-
cluded 17 participants and Ahmad 2001 included 21 participants.
The mean age of the participants in the two trials was 61 years and
64 years respectively (Ahmad 2001; Ardengh 2003). The propor-
tion of females in the two trials was 23.8% and 64.7% respectively
(Ahmad 2001; Ardengh 2003). The prevalence of unresectability
(pre-test probability) was 0.529 in Ardengh 2003 and 0.667 in
Ahmad 2001.
The tests that participants underwent prior to endoscopic ultra-
sound (EUS) were cross-sectional imaging (CT scan in all pa-
tients and ultrasound in some patients depending upon the re-
ferral centre) in Ahmad 2001, and CT scan and ultrasound in
Ardengh 2003 (on people undergoing pancreatic resection after
an ultrasound and a CT scan). Both studies evaluated endoscopic
ultrasound (EUS) as the index test. The reference standard was
surgeon’s judgement of unresectability in both studies. In Ahmad
2001, thiswas vascular invasionduring laparotomy,while Ardengh
2003 did not report the criteria that the surgeon used for assessing
unresectability during laparotomy.
We have provided themethodological quality of the included stud-
ies in the Methodological quality of included studies section.
Excluded studies
We excluded a total of 204 references for the following reasons.
1. Seventeen studies were not primary studies (Barthet 2007;
Brugge 1995; Faigel 1996; Fockens 1993; Freeny 2001;
García-Cano 2002; Gaspar 2015; Goh 2006; Lévy 2001;
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Malfertheiner 2005; Neoptolemos 2005; Pappas 2011; Rösch
1992c; Shin 2013; Snady 1993; Wang 2007a; Wiersema 2000).
2. We excluded 111 studies because participants were not
patients with CT resectable pancreatic cancer (Abe 2010; Ahmad
1999; Ahmad 2000a; Ahmad 2000c; Ahmad 2000d; Akahoshi
1998; Anand 2013; Aubertin 1996; Awad 1997; Baarir 1998;
Bao 2008; Bettini 2005; Broglia 2001; Burge 2015; Carroll
1999; Catalano 1997; Catalano 1998; Chandler 1999; Chhibber
2006; Chiang 2014; Cieslak 2014; Crippa 2013; Crippa 2014;
DeWitt 2004; Egorov 2012; Einersen 2013; Farma 2008a;
Fischer 2002; Frohlich 1999; Grenacher 2004; Lopez-Hänninen
2002; Hochwald 1999; Howard 1997; Hu 2015; Ichikawa 1997;
Iglesias-Garcia 2010; Imazu 2010; Izuishi 2010; Javery 2013;
Jemaa 2008; Kala 2007; Karoumpalis 2011; Kim 2001; Kim
2012; Koelblinger 2011; Koranda 2009; Koranda 2010; Kulig
2004; Kysucan 2010; Latronico 2005; Lee 2002; Lee 2010;
Lentschig 1996; Makowiec 2000; Maluf-Filho 2004; Mansfield
2008; McFarland 1996; Megibow 1995; Melzer 1996; Mertz
2000; Motosugi 2011; Mukai 1991; Murakami 1996;
Nakamoto 1999; Napolitano 2002; Nishiharu 1999; Palazzo
1993; Park 2009; Patel 2002a; Patel 2002b; Paul 2012; Ramsay
2004; Razzaque 2012; Reiser-Erkan 2009; Reiser-Erkan 2010;
Ren 2006; Ridtitid 2015; Rivadeneira 2003; Romijn 2000;
Rösch 1992a; Rösch 1992b; Schmidt 2004; Schwarz 2001;
Seicean 2008; Shami 2011; Sheng 2012; Smedby 1997;
Solodinina 2014b; Soriano 2001; Soriano 2004; Strobel 2008;
Tapper 2010; Tian 2008a; Tian 2008b; Tian 2008c; Tierney
2001; Tio 1986; Tio 1988; Tio 1990; Tomi 2005; Trede 1997;
Turowska 2009; Valinas 2002; Wakabayashi 2008; Wang 2007b;
Wang 2015; Warshaw 1990; Woerlein 2002; Younes 1999;
Yusoff 2003; Zhong 2005).
3. Thirteen studies had no separate data on patients with
pancreatic cancer (Arabul 2012; Buchs 2007; Casneuf 2007;
Cieslak 2012; Cieslak 2013; Dewitt 2003; Ho 2008; Lu 2006;
Lytras 2005; Pan 2014; Schima 2002; Takaori 2007; Tomazic
2000).
4. Two studies were not conducted in patients undergoing
pancreatic resections (Agarwal 2005; Xu 2014).
5. In 61 studies diagnostic accuracy data on unresectability
was unavailable (Ahmad 2000b; Arslan 2001; Artifon 2009;
Asagi 2013; Aslanian 2005; Baghbanian 2014; Brugge 1996;
Buscall 1999; Cahn 1996; Chang 1997; Chen 2001a; Chen
2001b; Chen 2009; Chiang 2012; Costilla 2011; Croome 2010;
Czako 2009; Delbeke 1999; Egorov 2013; Einersen 2014;
Eloubeidi 2006; Eloubeidi 2007; Erickson 2000; Farma 2008b;
Gress 1997; Gress 1999; Harrison 1999; Heinrich 2005;
Helmreich 2004; Hemmingsson 1982; Hirokawa 2010;
Holzapfel 2011; Kadish 1995; Kim 2015; Lakhtakia 2011;
Mehmet 2006; Morris-Stiff 2011; Prithiviraj 2013; Raj 2013;
Rösch 2000; Saif 2008; Shoup 2000; Sironi 1995; Sironi 1996;
Skordilis 2002; Snady 1994; Solodinina 2014a; Spencer 1998;
Staib 1997; Takayama 2009; Tellez-Avila 2012; Tio 1996; Wang
2008; Wang 2014; Wee 2012; Yao 2012; Yasuda 1988; Yasuda
1993; Yoneyama 2014; Zhang 2012; Zhang 2015).
Methodological quality of included studies
We have summarised the risk of bias and applicability concerns in
the included studies in Figure 3. As shown in Figure 3, there were
no applicability concerns in the included studies.However, the risk
of bias in the “patient selection” was high in Ardengh 2003 since
it excluded pancreatic cancers that were 3 cm or more in diameter.
The risk of bias in this domain was low in Ahmad 2001. The risk
of bias in the “index test” domain was unclear in Ardengh 2003
since it was unclear whether the index test results were interpreted
without knowledge of the results of the reference standard. The
risk of bias in this domain was low in Ahmad 2001. As anticipated,
both studies used surgeons’ judgement on unresectability as the
reference standard and so both studies were at unclear risk of bias
in the “reference standard” domain. Ardengh 2003 did not report
the interval between EUS and surgery and the participant flow.
We considered this study to be at unclear risk of bias in the “flow
and timing” domain. The risk of bias in this domain was low in
Ahmad 2001.
11Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with
curative intent in pancreatic and periampullary cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
Findings
There was no heterogeneity in sensitivity as shown by very good
overlap of confidence intervals (CIs) in the forest plots, visual-
isation of the receiver operating characteristic (ROC) plot, and
by the values of sensitivity which were almost identical (0.86 in
Ahmad 2001 versus 0.89 in Ardengh 2003) (Figure 4; Figure 5).
Although we planned to evaluate the use of univariate random-
effects model for specificity based on the forest plots (there was
good overlap of CIs but the difference in point estimate was more
with specificity than sensitivity: 0.71 in Ahmad 2001 versus 0.88
in Ardengh 2003) and ROC plot, the only model that converged
was univariate fixed-effect model for both sensitivity and speci-
ficity. So, we were unable to choose the best model by comparing
the −2 log likelihood.
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Figure 4. Pooled sensitivity and specificity of endoscopic ultrasound for assessing the resectability with
curative intent in pancreatic and periampullary cancer.Abbreviations: df: degrees of freedom.
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Figure 5. Summary ROC Plot of endoscopic ultrasound for assessing the resectability of pancreatic and
periampullary cancer.
The summary estimate of sensitivity for unresectability was 0.87
(95% CI 0.54 to 0.97) and the summary estimate of specificity
for unresectability was 0.80 (95% CI 0.40 to 0.96). The positive
likelihood ratio and negative likelihood ratio were 4.3 (95% CI
1.0 to 18.6) and 0.2 (95%CI 0.0 to 0.8) respectively. Although we
planned to calculate the post-test probabilities using the median
and quartiles of the pre-test probabilities, we calculated the post-
test probabilities using the mean and range of the pre-test proba-
bilities because of the inclusion of two studies only. The mean pre-
test probability was 60.5%. At this pre-test probability, the post-
test probability of unresectable disease for people with a positive
EUS (EUS indicating unresectability) was 86.9% (95%CI 60.9%
to 96.6%) and the post-test probability of unresectable disease
for people with a negative EUS (EUS indicating resectability) was
20.0% (5.1% to 53.7%). This means that 13% of people (95%CI
3% to 39%) with positive EUS have potentially resectable cancer
and 20% (5% to 53%) of people with negative EUS have unre-
sectable cancer. The “Summary of findings” table shows the post-
test probability of unresectable disease at different pre-test proba-
bilities of unresectable disease (Summary of findings).
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Neither of the included studies reported any complications related
to EUS. We did not perform any investigation of heterogeneity
because only two studies met the inclusion criteria of this review.
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Summary of findings
Population People with pancreat ic cancer found to resectable on computed tomography (CT)
scan
Setting Secondary or tert iary sett ing
Index test Endoscopic ultrasound (EUS)
Reference standard Laparotomy (surgeon’s judgement of unresectability)
Number of studies 2 studies (38 part icipants)
Summary sensitivity 0.87 (95% conf idence interval (CI) 0.54 to 0.97)
Summary specificity 0.80 (95% CI 0.40 to 0.96)
Consistent results Yes
Overall risk of bias Moderate to high
Other limitations 1. Both studies included pancreat ic cancers only.
2. One study included only part icipants with pancreat ic cancer less than 3 cm.
3. We could only perform the univariate f ixed-ef fect model and we were unable
to compare the model f it with other models.
Pre- test probability of unresectability
from included studies
Post- test probability of unresectability
in people with positive EUS (EUS indi-
cating unresectability)
(95% CI)
Post- test probability of unresectability
in people with negative EUS (EUS indi-
cating resectability)
(95% CI)
M inimum = 53% 83% (53% to 95%) 16% (4% to 46%)
M ean = 61% 87% (61% to 97%) 20% (5% to 54%)
M aximum = 67% 90% (67% to 97%) 25% (7% to 61%)
Interpretation There is signif icant uncertainty in the results because of inadequate data
We reported all probabilit ies in the table as percentages.
Abbreviat ions: CI: conf idence interval; EUS: endoscopic ultrasound.
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D I S C U S S I O N
Summary of main results
Only two studies (38 participants) that evaluated the diagnostic
accuracy of EUS in people with CT-resectable pancreatic cancers
met the inclusion criteria of this review. The summary estimate
of sensitivity was 0.87 (95% CI 0.54 to 0.97) and the summary
estimate of specificity was 0.81 (95% CI 0.40 to 0.96). The pos-
itive likelihood ratio and negative likelihood ratio were 4.3 (95%
CI 1.0 to 18.6) and 0.2 (95% CI 0.0 to 0.8) respectively. At the
mean pre-test probability in included studies (60.5%), the post-
test probability of unresectable disease for people with a positive
EUS (EUS indicating unresectability) was 86.9% (95%CI 60.9%
to 96.6%) and the post-test probability of unresectable disease
for people with a negative EUS (EUS indicating resectability) was
20.0% (5.1% to 53.7%).
Direct laparotomy after CT resulted in approximately 60%of can-
cers being unresectable, which appears to be higher than the usual
unresectability rates after CT scan of around 30% to 40% (Allen
2016). We are unable to identify why the pre-test probability of
unresectability was high in these centres which are specialist cen-
tres, considering that they have facilities to perform EUS. When
the EUS indicates that the pancreatic cancer is not resectable al-
though CT scan shows that pancreatic cancer is resectable (EUS
positive in CT resectable pancreatic cancer), approximately 13%
of people (95% CI 3% to 39%) had resectable pancreatic cancer.
Since pancreatic resection is the only potentially curative option
for pancreatic cancer, omission of laparotomy and resection in
these people can have a major negative impact on their survival.
We were unable to assess the diagnostic accuracy of MRI, PET,
PET-CT and compare their diagnostic accuracy with EUS since
none of the studies on MRI or PET were on CT resectable pan-
creatic cancers and none of the studies on PET-CT indicated the
added value of PET clearly.
Strengths and weaknesses of the review
We used formal search strategies and reported this, so that it is
possible to independently verify our results. Two review authors
independently identified studies and extracted data, thereby min-
imising human error in the selection of studies and data extrac-
tion. We reached agreement based on the information available in
the protocol of this review (Gurusamy 2015). The methodologi-
cal quality in one included study was as good as can be achieved
ethically (Ahmad 2001), and the methodological quality in the
second included study was mostly unclear (Ardengh 2003). There
were no concerns about applicability in either study. There was no
heterogeneity in the diagnostic test accuracy between the studies
as indicated by the almost identical sensitivities and good overlap
of CIs for specificities. These are themajor strengths of this review.
The major limitation of this review was the paucity of data: only
two studies met the inclusion criteria and both these studies were
on EUS. We had to use univariate fixed-effect models for both
sensitivity and specificity since this was the only model that con-
verged. Such models may give reliable and stable results if used in
the appropriate situation (Takwoingi 2015). Although we would
have liked to compare the model fit of the univariate fixed-effect
models thatwe performedwith themodel fit of univariate random-
effects model for at least specificity, this was not possible because
convergence was obtained only for univariate fixed-effect models
for both sensitivity and specificity. However, our decision is vin-
dicated to a certain extent by the almost identical sensitivity and
good overlap of CIs for specificity and the I² statistic values of 0%
for both sensitivity and specificity. The alternative was to present
the results of studies individually, which would have negated the
advantage of meta-analysis, i.e. improved precision, particularly
when there was no heterogeneity in the results between the two
studies.
Another limitation of this review is that we included sensitivity
maximising diagnostic filters for searching MEDLINE and Em-
base databases (Haynes 2004; Wilczynski 2005). This is because
the original searches without the filters retrievedmore than 40,000
references.We had to balance the possibility of missing some stud-
ies against the risk of being unable to complete the review. We
decided that it would be more useful to have evidence frommajor
studies rather than having no information at all. Notably, the di-
agnostic filters we used have a sensitivity of 98.6% for MEDLINE
and 100% for Embase. So, the chances of us missing some rele-
vant diagnostic studies are extremely low. We reduced this further
by performing a “related search” and “citing reference search” in
which we did not find any studies that we could include in this
review.
This is the first systematic review on the topic. EUS is not routinely
performed to assess resectability of pancreatic cancers in most cen-
tres and the findings from our review would suggest that there is
insufficient evidence of clinical benefit to justify its inclusion in
the standard diagnostic algorithm.
Applicability of findings to the review question
The findings of this review are applicable only to people with
pancreatic cancer who were found to be resectable after a CT scan.
In addition, all the participants included in this review underwent
laparotomy; so the findings of this review are applicable only in
those who are fit to withstand major surgery. This review assessed
the diagnostic accuracy of EUS in assessing the resectability of
pancreatic cancer and does not provide the diagnostic accuracy
of EUS in diagnosis of pancreatic cancer or finding the tumour,
node, and metastasis (TNM) staging of pancreatic cancer.
17Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with
curative intent in pancreatic and periampullary cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on two small studies, there is significant uncertainty in the
utility of endoscopic ultrasound (EUS) in people with pancreatic
cancer found to have resectable disease on computed tomography
(CT) scan. No studies have assessed the utility of EUS in people
with periampullary cancer.
There is no evidence to suggest that it should be performed rou-
tinely in people with pancreatic cancer or periampullary cancer
found to have resectable disease on CT scan.
Implications for research
1. Well-designed diagnostic test accuracy studies are needed to
reliably estimate the accuracy of diagnostic laparoscopy in people
with pancreatic and periampullary cancers. Comparison of
different imaging modalities with each other and with diagnostic
laparoscopy and laparoscopic ultrasound may further
demonstrate the value of the different imaging tests in staging
pancreatic and periampullary cancers.
2. The conclusion of this systematic review needs regular
review as the quality of CT scanning improves and the different
imaging tests should be compared with each other and diagnostic
laparoscopy and laparoscopic ultrasound in staging pancreatic
and periampullary cancers.
3. Cost-effectiveness studies should be undertaken to
determine whether EUS alone for EUS-negative CT resectable
pancreatic cancer and EUS plus diagnostic laparoscopy for EUS-
positive CT resectable pancreatic cancer should be routinely
performed in state funded clinical practice.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmad 2001
Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: unclear.






1. Patients undergoing potentially curative resection for pancreatic cancer.
2. Deemed to be resectable by previous cross-sectional imaging.
Setting: secondary/tertiary centre, USA.
Index tests Index test: endoscopic ultrasound (EUS).
Further details:
Technical specifications: Olympus (model: GF-UM20).
Performed by: endoscopists.
Criteria for positive diagnosis: vascular involvement as indicated by the loss of the hyperechoic vessel
wall/tumour interface, direct visualization of the tumour in the vascular lumen, and nonvisualisation
of a major vessel in the presence of collaterals. Preoperative imaging study criteria (by EUS or SVA)
for unresectability of pancreatic tumour included encasement or occlusion of the celiac axis, portal
vein, hepatic artery, superior mesenteric vein, or superior mesenteric artery
Target condition and reference
standard(s)
Target condition: unresectability.
Reference standard: surgical resection.
Further details:
Technical specifications: not applicable.
Performed by: surgeons.
Criteria for positive diagnosis: vascular invasion.
Flow and timing Number of indeterminates for whom the results of reference standard was available: 0 (0%).
Number of patients who were excluded from the analysis: 0 (0%)
Comparative
Notes Cross-sectional imaging used as pre-test (all underwent computed tomography (CT) scan, some
underwent ultrasound)
The study authors provided additional information regarding “Risk of bias” items and cross-sectional
imaging used
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Ahmad 2001 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Ardengh 2003
Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.






1. Patients undergoing potentially curative resection for pancreatic cancer (head of pancreas less
than 3 cm in diameter).
2. Deemed to be resectable by previous ultrasound and CT scan.
Setting: secondary/tertiary centre, Brazil.
Index tests Index test: EUS.
Further details:
Technical specifications: Pentax sectorial scanning echoendoscope (model: FG 32-UA or FG 36-
UX).
Performed by: endoscopists.
Criteria for positive diagnosis: tumour invading portal system or superior mesenteric artery (irreg-
ularity of the vessel wall or invasion by tumour or thrombus)
Target condition and reference
standard(s)
Target condition: unresectability.
Reference standard: surgical resection.
Further details:
Technical specifications: not applicable.
Performed by: surgeons.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard was available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes The study used ultrasound and CT scan as a pre-test.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
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Ardengh 2003 (Continued)




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Abbreviations: CT: computed tomography.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abe 2010 Not in patients with computed tomography (CT) resectable pancreatic cancer
Agarwal 2005 Not in patients undergoing pancreatic resections
Ahmad 1999 Not in patients with CT resectable pancreatic cancer
Ahmad 2000a Not in patients with CT resectable pancreatic cancer
Ahmad 2000b No diagnostic test accuracy data on unresectability
Ahmad 2000c Not in patients with CT resectable pancreatic cancer
Ahmad 2000d Not in patients with CT resectable pancreatic cancer
Akahoshi 1998 Not in patients with CT resectable pancreatic cancer
Anand 2013 Not in patients with CT resectable pancreatic cancer
Arabul 2012 No separate data on patients with pancreatic cancer
Arslan 2001 No diagnostic test accuracy data on unresectability
Artifon 2009 No diagnostic test accuracy data on unresectability
Asagi 2013 No diagnostic test accuracy data on unresectability
Aslanian 2005 No diagnostic test accuracy data on unresectability
Aubertin 1996 Not in patients with CT resectable pancreatic cancer
Awad 1997 Not in patients with CT resectable pancreatic cancer
Baarir 1998 Not in patients with CT resectable pancreatic cancer
Baghbanian 2014 No diagnostic test accuracy data on unresectability
Bao 2008 Not in patients with CT resectable pancreatic cancer
Barthet 2007 Review/editorial/letter to editor/commentary
Bettini 2005 Not in patients with CT resectable pancreatic cancer
Broglia 2001 Not in patients with CT resectable pancreatic cancer
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(Continued)
Brugge 1995 Review/editorial/letter to editor/commentary
Brugge 1996 No diagnostic test accuracy data on unresectability
Buchs 2007 No separate data on patients with pancreatic cancer
Burge 2015 Not in patients with CT resectable pancreatic cancer
Buscall 1999 No diagnostic test accuracy data on unresectability
Cahn 1996 No diagnostic test accuracy data on unresectability
Carroll 1999 Not in patients with CT resectable pancreatic cancer
Casneuf 2007 No separate data on patients with pancreatic cancer
Catalano 1997 Not in patients with CT resectable pancreatic cancer
Catalano 1998 Not in patients with CT resectable pancreatic cancer
Chandler 1999 Not in patients with CT resectable pancreatic cancer
Chang 1997 No diagnostic test accuracy data on unresectability
Chen 2001a No diagnostic test accuracy data on unresectability
Chen 2001b No diagnostic test accuracy data on unresectability
Chen 2009 No diagnostic test accuracy data on unresectability
Chhibber 2006 Not in patients with CT resectable pancreatic cancer
Chiang 2012 No diagnostic test accuracy data on unresectability
Chiang 2014 Not in patients with CT resectable pancreatic cancer
Cieslak 2012 No separate data on patients with pancreatic cancer
Cieslak 2013 No separate data on patients with pancreatic cancer
Cieslak 2014 Not in patients with CT resectable pancreatic cancer
Costilla 2011 No diagnostic test accuracy data on unresectability
Crippa 2013 Not in patients with CT resectable pancreatic cancer
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(Continued)
Crippa 2014 Not in patients with CT resectable pancreatic cancer
Croome 2010 No diagnostic test accuracy data on unresectability
Czako 2009 No diagnostic test accuracy data on unresectability
Delbeke 1999 No diagnostic test accuracy data on unresectability
Dewitt 2003 No separate data on patients with pancreatic cancer
DeWitt 2004 Not in patients with CT resectable pancreatic cancer
Egorov 2012 Not in patients with CT resectable pancreatic cancer
Egorov 2013 No diagnostic test accuracy data on unresectability
Einersen 2013 Not in patients with CT resectable pancreatic cancer
Einersen 2014 No diagnostic test accuracy data on unresectability
Eloubeidi 2006 No diagnostic test accuracy data on unresectability
Eloubeidi 2007 No diagnostic test accuracy data on unresectability
Erickson 2000 No diagnostic test accuracy data on unresectability
Faigel 1996 Review/editorial/letter to editor/commentary
Farma 2008a Not in patients with CT resectable pancreatic cancer
Farma 2008b No diagnostic test accuracy data on unresectability
Fischer 2002 Not in patients with CT resectable pancreatic cancer
Fockens 1993 Review/editorial/letter to editor/commentary
Freeny 2001 Review/editorial/letter to editor/commentary
Frohlich 1999 Not in patients with CT resectable pancreatic cancer
García-Cano 2002 Review/editorial/letter to editor/commentary
Gaspar 2015 Review/editorial/letter to editor/commentary
Goh 2006 Review/editorial/letter to editor/commentary
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(Continued)
Grenacher 2004 Not in patients with CT resectable pancreatic cancer
Gress 1997 No diagnostic test accuracy data on unresectability
Gress 1999 No diagnostic test accuracy data on unresectability
Harrison 1999 No diagnostic test accuracy data on unresectability
Heinrich 2005 No diagnostic test accuracy data on unresectability
Helmreich 2004 No diagnostic test accuracy data on unresectability
Hemmingsson 1982 No diagnostic test accuracy data on unresectability
Hirokawa 2010 No diagnostic test accuracy data on unresectability
Ho 2008 No separate data on patients with pancreatic cancer
Hochwald 1999 Not in patients with CT resectable pancreatic cancer
Holzapfel 2011 No diagnostic test accuracy data on unresectability
Howard 1997 Not in patients with CT resectable pancreatic cancer
Hu 2015 Not in patients with CT resectable pancreatic cancer
Ichikawa 1997 Not in patients with CT resectable pancreatic cancer
Iglesias-Garcia 2010 Not in patients with CT resectable pancreatic cancer
Imazu 2010 Not in patients with CT resectable pancreatic cancer
Izuishi 2010 Not in patients with CT resectable pancreatic cancer
Javery 2013 Not in patients with CT resectable pancreatic cancer
Jemaa 2008 Not in patients with CT resectable pancreatic cancer
Kadish 1995 No diagnostic test accuracy data on unresectability
Kala 2007 Not in patients with CT resectable pancreatic cancer
Karoumpalis 2011 Not in patients with CT resectable pancreatic cancer
Kim 2001 Not in patients with CT resectable pancreatic cancer
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(Continued)
Kim 2012 Not in patients with CT resectable pancreatic cancer
Kim 2015 No diagnostic test accuracy data on unresectability
Koelblinger 2011 Not in patients with CT resectable pancreatic cancer
Koranda 2009 Not in patients with CT resectable pancreatic cancer
Koranda 2010 Not in patients with CT resectable pancreatic cancer
Kulig 2004 Not in patients with CT resectable pancreatic cancer
Kysucan 2010 Not in patients with CT resectable pancreatic cancer
Lakhtakia 2011 No diagnostic test accuracy data on unresectability
Latronico 2005 Not in patients with CT resectable pancreatic cancer
Lee 2002 Not in patients with CT resectable pancreatic cancer
Lee 2010 Not in patients with CT resectable pancreatic cancer
Lentschig 1996 Not in patients with CT resectable pancreatic cancer
Lopez-Hänninen 2002 Not in patients with CT resectable pancreatic cancer
Lu 2006 No separate data on patients with pancreatic cancer
Lytras 2005 No separate data on patients with pancreatic cancer
Lévy 2001 Review/editorial/letter to editor/commentary
Makowiec 2000 Not in patients with CT resectable pancreatic cancer
Malfertheiner 2005 Review/editorial/letter to editor/commentary
Maluf-Filho 2004 Not in patients with CT resectable pancreatic cancer
Mansfield 2008 Not in patients with CT resectable pancreatic cancer
McFarland 1996 Not in patients with CT resectable pancreatic cancer
Megibow 1995 Not in patients with CT resectable pancreatic cancer
Mehmet 2006 No diagnostic test accuracy data on unresectability
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(Continued)
Melzer 1996 Not in patients with CT resectable pancreatic cancer
Mertz 2000 Not in patients with CT resectable pancreatic cancer
Morris-Stiff 2011 No diagnostic test accuracy data on unresectability
Motosugi 2011 Not in patients with CT resectable pancreatic cancer
Mukai 1991 Not in patients with CT resectable pancreatic cancer
Murakami 1996 Not in patients with CT resectable pancreatic cancer
Nakamoto 1999 Not in patients with CT resectable pancreatic cancer
Napolitano 2002 Not in patients with CT resectable pancreatic cancer
Neoptolemos 2005 Review/editorial/letter to editor/commentary
Nishiharu 1999 Not in patients with CT resectable pancreatic cancer
Palazzo 1993 Not in patients with CT resectable pancreatic cancer
Pan 2014 No separate data on patients with pancreatic cancer
Pappas 2011 Review/editorial/letter to editor/commentary
Park 2009 Not in patients with CT resectable pancreatic cancer
Patel 2002a Not in patients with CT resectable pancreatic cancer
Patel 2002b Not in patients with CT resectable pancreatic cancer
Paul 2012 Not in patients with CT resectable pancreatic cancer
Prithiviraj 2013 No diagnostic test accuracy data on unresectability
Raj 2013 No diagnostic test accuracy data on unresectability
Ramsay 2004 Not in patients with CT resectable pancreatic cancer
Razzaque 2012 Not in patients with CT resectable pancreatic cancer
Reiser-Erkan 2009 Not in patients with CT resectable pancreatic cancer
Reiser-Erkan 2010 Not in patients with CT resectable pancreatic cancer
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Ren 2006 Not in patients with CT resectable pancreatic cancer
Ridtitid 2015 Not in patients with CT resectable pancreatic cancer
Rivadeneira 2003 Not in patients with CT resectable pancreatic cancer
Romijn 2000 Not in patients with CT resectable pancreatic cancer
Rösch 1992a Not in patients with CT resectable pancreatic cancer
Rösch 1992b Not in patients with CT resectable pancreatic cancer
Rösch 1992c Review/editorial/letter to editor/commentary
Rösch 2000 No diagnostic test accuracy data on unresectability
Saif 2008 No diagnostic test accuracy data on unresectability
Schima 2002 No separate data on patients with pancreatic cancer
Schmidt 2004 Not in patients with CT resectable pancreatic cancer
Schwarz 2001 Not in patients with CT resectable pancreatic cancer
Seicean 2008 Not in patients with CT resectable pancreatic cancer
Shami 2011 Not in patients with CT resectable pancreatic cancer
Sheng 2012 Not in patients with CT resectable pancreatic cancer
Shin 2013 Review/editorial/letter to editor/commentary
Shoup 2000 No diagnostic test accuracy data on unresectability
Sironi 1995 No diagnostic test accuracy data on unresectability
Sironi 1996 No diagnostic test accuracy data on unresectability
Skordilis 2002 No diagnostic test accuracy data on unresectability
Smedby 1997 Not in patients with CT resectable pancreatic cancer
Snady 1993 Review/editorial/letter to editor/commentary
Snady 1994 No diagnostic test accuracy data on unresectability
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Solodinina 2014a No diagnostic test accuracy data on unresectability
Solodinina 2014b Not in patients with CT resectable pancreatic cancer
Soriano 2001 Not in patients with CT resectable pancreatic cancer
Soriano 2004 Not in patients with CT resectable pancreatic cancer
Spencer 1998 No diagnostic test accuracy data on unresectability
Staib 1997 No diagnostic test accuracy data on unresectability
Strobel 2008 Not in patients with CT resectable pancreatic cancer
Takaori 2007 No separate data on patients with pancreatic cancer
Takayama 2009 No diagnostic test accuracy data on unresectability
Tapper 2010 Not in patients with CT resectable pancreatic cancer
Tellez-Avila 2012 No diagnostic test accuracy data on unresectability
Tian 2008a Not in patients with CT resectable pancreatic cancer
Tian 2008b Not in patients with CT resectable pancreatic cancer
Tian 2008c Not in patients with CT resectable pancreatic cancer
Tierney 2001 Not in patients with CT resectable pancreatic cancer
Tio 1986 Not in patients with CT resectable pancreatic cancer
Tio 1988 Not in patients with CT resectable pancreatic cancer
Tio 1990 Not in patients with CT resectable pancreatic cancer
Tio 1996 No diagnostic test accuracy data on unresectability
Tomazic 2000 No separate data on patients with pancreatic cancer
Tomi 2005 Not in patients with CT resectable pancreatic cancer
Trede 1997 Not in patients with CT resectable pancreatic cancer
Turowska 2009 Not in patients with CT resectable pancreatic cancer
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(Continued)
Valinas 2002 Not in patients with CT resectable pancreatic cancer
Wakabayashi 2008 Not in patients with CT resectable pancreatic cancer
Wang 2007a Review/editorial/letter to editor/commentary
Wang 2007b Not in patients with CT resectable pancreatic cancer
Wang 2008 No diagnostic test accuracy data on unresectability
Wang 2014 No diagnostic test accuracy data on unresectability
Wang 2015 Not in patients with CT resectable pancreatic cancer
Warshaw 1990 Not in patients with CT resectable pancreatic cancer
Wee 2012 No diagnostic test accuracy data on unresectability
Wiersema 2000 Review/editorial/letter to editor/commentary
Woerlein 2002 Not in patients with CT resectable pancreatic cancer
Xu 2014 Not in patients undergoing pancreatic resections
Yao 2012 No diagnostic test accuracy data on unresectability
Yasuda 1988 No diagnostic test accuracy data on unresectability
Yasuda 1993 No diagnostic test accuracy data on unresectability
Yoneyama 2014 No diagnostic test accuracy data on unresectability
Younes 1999 Not in patients with CT resectable pancreatic cancer
Yusoff 2003 Not in patients with CT resectable pancreatic cancer
Zhang 2012 No diagnostic test accuracy data on unresectability
Zhang 2015 No diagnostic test accuracy data on unresectability
Zhong 2005 Not in patients with CT resectable pancreatic cancer
Abbreviations: CT: computed tomography.
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D A T A
Presented below are all the data for all of the tests entered into the review.






1 EUS 2 38
Test 1. EUS.
Review: Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic
and periampullary cancer
Test: 1 EUS
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ahmad 2001 12 2 2 5 0.86 [ 0.57, 0.98 ] 0.71 [ 0.29, 0.96 ]
Ardengh 2003 8 1 1 7 0.89 [ 0.52, 1.00 ] 0.88 [ 0.47, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. QUADAS-2 classification
Domain 1: patient selection Patient sampling Patients with pancreatic and periampullary
cancer considered eligible for surgical re-
section following a computed tomography
(CT) scan
Was a consecutive or random sample of pa-
tients enrolled?
Yes: if the study included a consecutive
sample or a random sample of patients with
pancreatic and periampullary cancer eligi-
ble for surgical resection after CT scan.
No: if the study did not include a consecu-
tive sample or a random sample of patients
with pancreatic and periampullary cancer
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Table 1. QUADAS-2 classification (Continued)
eligible for surgical resection after CT scan.
Unclear: if this information was unavail-
able.
Was a case-control design avoided? Yes: if the study assessed a cohort of patients
about to undergo surgical resection.
No: if the study compared patients who
underwent unsuccessful laparotomy (cases)
with patients who underwent successful
surgical resection (controls).We planned to
exclude such studies but did not find any
case-control studies that met the other in-
clusion criteria.
Unclear: as anticipated, we were able to de-
termine whether the design was case-con-
trol
Did the study avoid inappropriate exclu-
sions?
Yes: if the study included all patients with
pancreatic and periampullary cancer eligi-
ble for surgical resection.
No: if the study excluded patients based on
high probability of resectability (for exam-
ple, small tumours).
Unclear: if this information was unavail-
able.
Could the selection of patients have intro-
duced bias?
Low risk of bias: if “yes” classification for
all the above 3 questions
High risk of bias: if “no” classification for
any of the above 3 questions
Unclear risk of bias: if “unclear” classifica-
tion for any of the above 3 questions but
without a “no” classification for any of the
above 3 questions
Patient characteristics and setting Yes: we included only patients with pan-
creatic and periampullary cancer who were
considered eligible for surgical resection
following a CT scan. So, we anticipated
that we would classify all the included stud-
ies as “yes”.
No: we excluded studies that considered
patients unsuitable for surgery after a CT
scan. So, we did not use this classification.
Unclear: we excluded studies in which it
is unclear whether the patients had under-
gone CT scan following which they were
still considered suitable for surgical resec-
tion. So, we classified all studies included
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Table 1. QUADAS-2 classification (Continued)
in the review as “yes” for this item, as an-
ticipated
Are there concerns that the included pa-
tients and setting do not match the review
question?
Considering the inclusion criteria of this
review, as anticipated, we classified all the
included studies as “low concern”
Domain 2: index test Index test(s) Magnetic res-
onance imaging (MRI), positron emission
tomography (PET), PET-CT, endoscopic
ultrasound (EUS)
Were the index test results interpretedwith-
out knowledge of the results of the refer-
ence standard?
The index test would always be conducted
though not interpreted before the reference
standard
Yes: if the index test was conducted and
interpreted without the knowledge of the
results of the reference standard.
No: if the index test was interpreted with
the knowledge of the results of the reference
standard.
Unclear: if it was unclear whether the index
test was interpreted without the knowledge
of the results of the reference standard
If a threshold was used, was it prespecified? Not applicable.
Could the conduct or interpretation of the
index test have introduced bias?
Low risk of bias: if “yes” classification for
the only relevant question in this domain
High risk of bias: if “no” classification for
the only relevant question in this domain
Unclear risk of bias: if “unclear” classifica-
tion for the only relevant question in this
domain
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
Low concern: if the criteria for positive in-
dex test was clearly stated
High concern: if the criteria for positive
index test was not stated
Domain 3: target condition and refer-
ence standard
Target condition and reference standard(s) Unresectability. The reasons for unre-
sectability include involvement of adjacent
structures or distant metastases. There is
currently no universal criteria for unre-
sectability. Consensus exists for the def-
inition of borderline resectable cancers (
Abrams 2009). Therefore, where there is
less tissue involvement than in a borderline
resectable cancer the tumour can be con-
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Table 1. QUADAS-2 classification (Continued)
sidered as resectable
Positive reference standard: confirmation
of liver or peritoneal involvement by
histopathological examination of suspi-
cious (liver or peritoneal) lesions (irre-
spective of how the tissues were obtained
for histopathological examination). We ac-
cepted only paraffin section histology as the
reference standard. We also accepted the
surgeon’s judgement of unresectability on
laparotomy when biopsy confirmation was
not possible (for example, the surgeon may
not resect the tumour if it invaded the ad-
jacent blood vessels but would not obtain a
biopsy confirmation of this because of the
danger posed by resecting a part of a large
blood vessel). However, it should be noted
that surgeon’s judgement of unresectability
at laparotomy is a subjective decision and
is a possible source of error in the reference
standard but in the absence of an ethical
and true gold standard, we accepted this as
a reference standard
Negative reference standard: cancer was
fully resected i.e. clear resectionmargins on
histology
Is the reference standards likely to correctly
classify the target condition?
Yes: if histological confirmation of distant
spread or local infiltration of adjacent struc-
tures making the cancer unresectable was
obtained. The report on the resection mar-
gins shows clearly that the cancer had been
completely resected. As anticipated, none
of the included studies met these criteria
because of the danger that biopsy of infil-
tration of adjacent structures poses.
No: if resection margins were not clear of
cancer.
Unclear: if surgeons’ judgement was used
to assess unresectability or if the informa-
tion about the resection margins was un-
available. As anticipated, we classified both
included studies as “unclear” because the
studies used the surgeons’ judgement as a
criterion for unresectability
Were the reference standard results inter-
preted without knowledge of the results of
the index tests?
Yes: if the reference standard was inter-
pretedwithout the knowledge of the results
of the index test.
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Table 1. QUADAS-2 classification (Continued)
No: if the reference standard was inter-
preted with the knowledge of the results of
the index test.
Unclear: it was unclear if the reference stan-
dard was interpreted without the knowl-
edge of the results of the index test
However, the results of the index test are
unlikely to influence the results of the ref-
erence standard. So, we did not take the
answer to this question into account to de-
termine the risk of bias
Could the reference standard, its conduct,
or its interpretation have introduced bias?
We determined the risk of bias as “low” if
the answer to the first question was “yes”,
“high” if the answer to the first question
was “no”, and “unclear” if the answer to the
first question was “unclear”
Are there concerns that the target condition
as defined by the reference standard does
not match the question?
Considering the inclusion criteria for this
review, we classified all the included studies
as “low concern”, as anticipated
Domain 4: flow and timing Flow and timing The cancer may progress if there is a long
time interval between index test and laparo-
tomy. So, we chose an arbitrary time inter-
val of 2 months as an acceptable time in-
terval between index test and laparotomy
Was there an appropriate interval between
index test and reference standard?
Yes: if the time interval between index test
and laparotomy was less than 2 months.
No: if the time interval between index test
and laparotomy was more than 2 months.
Unclear: if the time interval between index
test and laparotomy was unclear
Did all patients receive the same reference
standard?
Yes: if all the patients received the same
reference standard (we classified all the in-
cluded studies as “yes”, as anticipated).
No: if different patients received different
reference standards
Unclear: if this information was unclear.
Were all patients included in the analysis? Yes: if the study included all the patients
in the analysis irrespective of whether the
results were uninterpretable.
No: if the study excluded some patients
from the analysis because of uninter-
pretable results.
Unclear: if this information was unclear.
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Could the patient flow have introduced
bias?
Low risk of bias: if “yes” classification for
all the above 3 questions
High risk of bias: if “no” classification for
any of the above 3 questions
Unclear risk of bias: if “unclear” classifica-
tion for any of the above 3 questions but
without a “no” classification for any of the
above 3 questions
Abbreviations: CT: computed tomography; EUS: endoscopic ultrasound; MRI: magnetic resonance imaging; PET: positron emission
tomography.
A P P E N D I C E S
Appendix 1. Glossary of terms
Adjuvant: treatment provided in addition to another treatment with an aim to improve the effectiveness of another treatment.
Algorithm: order in which diagnostic tests are performed and actions taken depending upon their results (in this context).
Ampulla of Vater: area where the pancreatic duct and common bile duct meet.
Chemotherapy: medication used to treat or control cancer (in this context).
Disseminated: spread of cancer (in this context).
Distal: left side of pancreas (in this context).
Duodenum: first part of the small intestine.
Histology: examination of tissues under a microscope.
Lesions: abnormal changes in the structure of all or part of an organ due to disease or injury.
Mortality: death.
Paraffin: wax.
Peritoneal: relating to the membrane that lines the walls of the abdominal and pelvic cavities.
Resection: removal of part of an organ (in this context, the pancreas).
Appendix 2. MEDLINE (OvidSP) search strategy
(In-Process & Other Non-Indexed Citations and Ovid MEDLINE)
1. (ampulla vateri or ampullovateric or papilla vateri or vater papilla or vater ampulla or periampull* or peri-ampull* or choledoch* or
alcholedoch* or bile duct* or biliary or cholangio* or gall duct or duoden* or small bowel or small intestin* or enter* or pancrea*).ti,ab.
2. exp “Ampulla of Vater”/su [Surgery]
3. 1 or 2
4. (carcin* or cancer* or neoplas* or tumour* or tumor* or cyst* or growth* or adenocarcin* or malign*).ti,ab.
5. 3 and 4
6. Duodenal Neoplasms/su [Surgery]
7. exp Pancreatic Neoplasms/su [Surgery]
8. Common Bile Duct Neoplasms/su [Surgery]
9. 5 or 6 or 7 or 8
10. (surger* or surgical* or operat* or resection* or preoperative).ti,ab.
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11. exp Surgical Procedures, Operative/ or General Surgery/
12. 10 or 11
13. 9 and 12
14. (pancreatect* or pancreaticojejunost* or pancreaticogastros* or pancreaticoduodenect* or duodenopancreatectom* or pancreato-
biliary).ti,ab.
15. pancreatectomy/ or pancreaticoduodenectomy/ or pancreaticojejunostomy/
16. 13 or 14 or 15
17. (PET or MRI or NMRI or zeugmatogra* or ((emission or positron or magneti* or MR or NMR or proton or acoustic or ARFI)
and (tomogra* or scan or scans or imaging))).ti,ab.
18. Positron-Emission Tomography/
19. exp Magnetic Resonance Imaging/
20. 17 or 18 or 19
21. Endosonography/
22. (endosonogra* or EUS).ti,ab.
23. (echogra* or ultrason* or ultrasound).ti,ab.
24. exp Ultrasonography/
25. 23 or 24
26. endoscop*.ti,ab.
27. exp Endoscopy/
28. 26 or 27
29. 25 and 28
30. 20 or 21 or 22 or 29
31. 16 and 30
32. sensitiv:.mp. OR diagnos:.mp. OR di.fs.
33. 31 and 32
Appendix 3. Embase (OvidSP) search strategy
1. ((ampulla vateri or ampullovateric or papilla vateri or vater papilla or vater ampulla or periampull* or peri-ampull* or choledoch* or
alcholedoch* or bile duct* or biliary or cholangio* or gall duct or duoden* or small bowel or small intestin* or pancrea*) and (carcin*
or cancer* or neoplas* or tumour* or tumor* or cyst* or growth* or adenocarcin* or malign*)).ti,ab.
2. exp duodenum cancer/su [Surgery]
3. Vater papilla tumor/su [Surgery]
4. exp pancreas cancer/su [Surgery]
5. exp bile duct tumor/su [Surgery]
6. 1 or 2 or 3 or 4 or 5
7. (surger* or surgical* or operat* or resection* or preoperative).ti,ab.
8. exp Surgery/
9. 7 or 8
10. 6 and 9
11. (pancreatect* or pancreaticojejunost* or pancreaticogastros* or pancreaticoduodenect* or duodenopancreatectom* or pancreato-
biliary).ti,ab.
12. exp pancreas surgery/
13. 10 or 11 or 12
14. (PET or MRI or NMRI or zeugmatogra* or ((emission or positron or magneti* or MR or NMR or proton or acoustic or ARFI)
and (tomogra* or scan or scans or imaging))).ti,ab.
15. positron emission tomography/di
16. exp nuclear magnetic resonance imaging/di
17. 14 or 15 or 16
18. endoscopic echography/
19. (endosonogra* or EUS).ti,ab.
20. (echogra* or ultrason* or ultrasound).ti,ab.
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21. exp ultrasound/
22. 20 or 21
23. endoscop*.ti,ab.
24. exp gastrointestinal endoscopy/
25. 23 or 24
26. 22 and 25
27. 17 or 18 or 19 or 26
28. 13 and 27
29. di.fs. OR predict:.tw. OR specificity.tw.
30. 28 and 29
Appendix 4. Science Citation Index (Web of Knowledge) search strategy
(Includes: Conference Proceedings Citation Index- Science)
#1TS=(((ampulla vateri or ampullovateric or papilla vateri or vater papilla or vater ampulla or periampull* or peri-ampull* or choledoch*
or alcholedoch* or bile duct* or biliary or cholangio* or gall duct or duoden* or small bowel or small intestin* or pancrea*) and (carcin*
or cancer* or neoplas* or tumour* or tumor* or cyst* or growth* or adenocarcin* or malign*)))
#2 TS=(operat* OR surger* OR surgical* OR resection* OR preoperative)
#3 #1 AND #2
#4 TS=(pancreatect* OR pancreaticojejunost* OR pancreaticogastros* OR pancreaticoduodenect* OR duodenopancreatectom* OR
pancreato-biliary)
#5 #3 OR #4
#6 TS=(PET OR MRI OR NMRI OR zeugmatogra* OR ((emission OR positron OR magneti* OR MR OR NMR OR proton OR
acoustic OR ARFI) AND (tomogra* OR scan OR scans OR imaging)) OR endosonogra* OR EUS OR ((echogra* OR ultrason* OR
ultrasound) AND endoscop*))
#7 #5 AND #6
Appendix 5. National Institute for Health Research - Health Technology Assessment (Centre for
Reviews and Dissemination)
pancrea* Or periampullary
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. We included sensitivity maximising diagnostic filters for searching MEDLINE and Embase databases (Haynes 2004; Wilczynski
2005). This is because the original searches without the filters retrieved more than 40,000 references. We had to balance the
possibility of missing some studies against the risk of being unable to complete the review at all. We decided that it is useful to have
evidence from major studies rather than having no information at all.
2. We performed the related search function through MEDLINE (OvidSP) rather than MEDLINE (Pubmed), and also performed
a cited reference search in MEDLINE (via OvidSP).
3. We simplified the analysis in the presence of sparse data based on Takwoingi 2015.
4. We revised the plan to investigate heterogeneity by using a hierarchical summary receiver operating characteristics (HSROC)
model rather than a bivariate model. This would allow the inclusion of studies with different thresholds in the model, and potentially
overcome the problem with sparse data.
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